Persistent Depressive Disorder: An Illustration of the Evolution and Future of Clinical Psychology (With CE)
$40.00
Presenter: Dr. J. Kim Penberthy
Overview:
The history of treatment for persistent depressive disorder, or what used to be known as depressive personality disorder, then dysthymia, or chronic major depression, or double depression, is an example of the evolving and increasingly innovative assessment and therapeutic strategies used in clinical and health psychology. The diagnostic criteria of this group of depressive symptoms has evolved over time and appears to have come full circle in many ways. Assessment has arguably evolved at a slower rate, with many of us still using self-report data to diagnose, yet innovative and exciting assessment strategies are developing in our research labs and in the field. Psychotherapy approaches for this “treatment resistant” disorder have changed over the decades. From the early psychoanalytic approaches to basic behavioral activation, and cognitive behavioral therapy (CBT), most therapies have had only limited success in reducing depressive symptoms long term. Contextual therapeutic approaches including Cognitive Behavioral Analysis System of Psychotherapy (CBASP), Mindfulness-Based CBT, and Acceptance and Commitment Therapy (ACT) have been developed and researched with more success, and yet, still many individuals with persisting depressive symptoms find little to no relief. Thus, the evolution of treatment approaches continues, with the recent arrival of psychedelic assisted psychotherapy for these persistent depressive disorders and some intriguing and encouraging findings in the use of ketamine and other substances. Additionally, ongoing work in the use of mindfulness and contemplative based psychotherapies has demonstrated an interest from the field and usefulness in preventing relapse. The future of the treatment of PDD, much like the future of clinical and health psychology, continues to look promising with the expanding role of innovative technology including tailoring treatment approaches based on genetics, psychophysiological, and behavioral information, as well as the use of machine learning to help match psychologists with patients in order to promote effective therapeutic relationships and equitable treatment access.
Learning Objectives: Intended Audience: All
- Describe the changes in the diagnosis of what is now referred to as PDD.
- Describe how ideas of assessment and diagnosis are evolving in clinical and health psychology.
- Describe the evolving psychotherapy approaches to PDD over the years.
- List examples of the innovations happening in clinical and health psychology, specifically related to assessment and treatment of PDD.
Attendees must attend the entirety of the program and complete the Evaluation sent after the program. Evaluations will be sent via email shortly after the Live webinar. CE Certificates will be processed and emailed within 5 – 10 business days from Live Webinar.
Cost: Free for Members and $50 for Non-Members (NOTE: Members must be signed in to get the discounted rate. If you have trouble signing in, contact us).
PLEASE NOTE: You must sign in to receive the Member discount. After purchasing, you must follow the link in your receipt provided to REGISTER for the webinar via Zoom. It is a 2-step process. If a link does not appear, contact us.
Cancellation Policy: No refunds will be provided except when SCP cancels the webinar.
The Society of Clinical Psychology, Division 12 nor Dr. Penberthy have commercial support for the content of this webinar including endorsement of products, conflict of interest including but not limited to research grants, royalties for books or training, commercial support from companies or pharmaceutical sponsorship.
If you require any special needs assistance, please contact the SCP Central Office at division12apa@gmail.com.
Description
Presenter: Dr. J. Kim Penberthy
Overview:
The history of treatment for persistent depressive disorder, or what used to be known as depressive personality disorder, then dysthymia, or chronic major depression, or double depression, is an example of the evolving and increasingly innovative assessment and therapeutic strategies used in clinical and health psychology. The diagnostic criteria of this group of depressive symptoms has evolved over time and appears to have come full circle in many ways. Assessment has arguably evolved at a slower rate, with many of us still using self-report data to diagnose, yet innovative and exciting assessment strategies are developing in our research labs and in the field. Psychotherapy approaches for this “treatment resistant” disorder have changed over the decades. From the early psychoanalytic approaches to basic behavioral activation, and cognitive behavioral therapy (CBT), most therapies have had only limited success in reducing depressive symptoms long term. Contextual therapeutic approaches including Cognitive Behavioral Analysis System of Psychotherapy (CBASP), Mindfulness-Based CBT, and Acceptance and Commitment Therapy (ACT) have been developed and researched with more success, and yet, still many individuals with persisting depressive symptoms find little to no relief. Thus, the evolution of treatment approaches continues, with the recent arrival of psychedelic assisted psychotherapy for these persistent depressive disorders and some intriguing and encouraging findings in the use of ketamine and other substances. Additionally, ongoing work in the use of mindfulness and contemplative based psychotherapies has demonstrated an interest from the field and usefulness in preventing relapse. The future of the treatment of PDD, much like the future of clinical and health psychology, continues to look promising with the expanding role of innovative technology including tailoring treatment approaches based on genetics, psychophysiological, and behavioral information, as well as the use of machine learning to help match psychologists with patients in order to promote effective therapeutic relationships and equitable treatment access.
Learning Objectives: Intended Audience: All
- Describe the changes in the diagnosis of what is now referred to as PDD.
- Describe how ideas of assessment and diagnosis are evolving in clinical and health psychology.
- Describe the evolving psychotherapy approaches to PDD over the years.
- List examples of the innovations happening in clinical and health psychology, specifically related to assessment and treatment of PDD.
Attendees must attend the entirety of the program and complete the Evaluation sent after the program. Evaluations will be sent via email shortly after the Live webinar. CE Certificates will be processed and emailed within 5 – 10 business days from Live Webinar.
Cost: Free for Members and $50 for Non-Members (NOTE: Members must be signed in to get the discounted rate. If you have trouble signing in, contact us).
PLEASE NOTE: You must sign in to receive the Member discount. After purchasing, you must follow the link in your receipt provided to REGISTER for the webinar via Zoom. It is a 2-step process. If a link does not appear, contact us.
Cancellation Policy: No refunds will be provided except when SCP cancels the webinar.
The Society of Clinical Psychology, Division 12 nor Dr. Penberthy have commercial support for the content of this webinar including endorsement of products, conflict of interest including but not limited to research grants, royalties for books or training, commercial support from companies or pharmaceutical sponsorship.
If you require any special needs assistance, please contact the SCP Central Office at division12apa@gmail.com.
Reviews
There are no reviews yet.